Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 14, 2005
- Nippon Shinyaku Forecasts 2.1% Growth in Sales for FY2004
March 14, 2005
- PRESS SEMINAR
March 14, 2005
- Mochida's R&D to Focus on Lifestyle Diseases, Chronic Pain
March 14, 2005
- OTC NEWS IN BRIEF
March 14, 2005
- VIWES & OPINIONS
March 14, 2005
- MEDICAL DEVICE NEWS IN BRIEF
March 14, 2005
- Aiming for \1 Tril. in Sales in FY2011: Mr Naito of Eisai
March 14, 2005
- Sales of Pfizer Japan Increase 25.2% to \385.6 Bil.
March 14, 2005
- Committee Recommends Approval of In Vivo Diagnostic Adenosine
March 14, 2005
- Japan Pharmaceutical Roundtable-Economist Conference
March 14, 2005
- 5 Drugs Including Vfend Recommended for Approval
March 14, 2005
- BUSINESS NEWS IN BRIEF
March 14, 2005
- Interstitial Pneumonia Due to Arava Evaluated: Safety Inf. No. 201
March 14, 2005
- DIAGNOSTIC NEWS IN BRIEF
March 14, 2005
- PMDA Suspends Receipt of Applications for Clinical Trial Consultation
March 14, 2005
- TOPICS 2 articrels
March 14, 2005
- 3-Year Plan on Clinical Trials Enters Last Year
March 14, 2005
- BULLETIN
March 14, 2005
- SJP SEMINAR
March 14, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…